1. Aggregated particles containing nanodispersed particles of the drug umeclidinium bromide and vilanterol triphenatate, where the aggregated particles have a median aerodynamic diameter of less than about 100 microns, and additionally where the nanodispersed particles of the drug have an effective average particle size of less than about 1000 nm. . The aggregated particles of claim 1, wherein the ratio of umeclidinium to vilanterol is 5: 1.3. The aggregated particles according to claim 1, also containing nanodispersed particles of the drug fluticasone furoate. The aggregated particles of claim 3, wherein the ratio of omeclidinium to fluticasone furoate is 1.25: 1.5. Aggregated particles according to claim 1, where the aggregated particles also contain nanodispersed particles of one or more excipients. The aggregated particles of claim 5, wherein the nanodispersed excipient particles comprise magnesium stearate. The aggregated particles of claim 1, wherein the aggregated particles have a mass-median aerodynamic diameter of from about 1 μm to about 6 μm. The aggregated particles of claim 1, wherein the nanodispersed drug particles have an effective average particle size of less than about 400 nm. Aggregated particles according to paragraphs. 1-8, for use in the treatment of a respiratory disease such as asthma or COPD. 10. A powder composition containing aggregated particles according to any one of paragraphs. 1-9 and one or more pharmaceutically acceptable excipients. 11. The powder composition of claim 10, wherein the pharmaceutically acceptable excipient contains lactose and optionally magnesium stearate. The powder composition according to claim 10 or 11, for use in the treatment of a respiratory disease such as asthma or1. Агрегированные частицы, содержащие нанодисперсные частицы лекарственного средства умеклидиния бромида и вилантерола трифенатата, где агрегированные частицы обладают масс-медианным аэродинамическим диаметром менее чем примерно 100 мкм, и дополн
